Our findings emphasize the importance of pre-screening wt-EGFR NSCLC patients for BRG1 status, identifying two distinct subsets: those with wt-EGFR/wt-BRG1 who may benefit from EGFR-TKI therapy, and those with wt-EGFR/mt-BRG1 who might benefit from AKT inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.